Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cellegy Canada Inc.

Division of Adamis Pharmaceuticals Corp.

Latest From Human Genome Sciences Inc.

GSK's Immunology Strategy Edges Closer To Delivering

GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.

Immune Disorders Business Strategies

Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow

Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.

BioPharmaceutical Regulation

Merck’s Bezlotoxumab C. Difficile Data Pave Way For Antibodies

Company readies regulatory filings for bezlotoxumab as a monotherapy in preventing C. difficile, following presentation of positive MODIFY I and II data at the ICAAC meeting in San Diego.

Clinical Trials

J&J/Pharmacyclics' ibrutinib gets extra CHMP tick for IgM cancer

The European Medicine Agency's scientific advisors group recommended on 22 May that Imbruvica (ibrutinib) should be indicated for the treatment of Waldenstr?m’s macroglobulinaemia (WM), a very rare blood cell cancer characterized by vast overproduction of immunoglobulin M (IgM). The recent approval of ibrutinib in the US, and its imminent approval in Europe not only provide WM patients with first- and second-line treatment options, but also, says one key opinion leader in WM, will provide a focus for more productively organized patient group and physician activity.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Vaxis Therapeutics Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Adamis Pharmaceuticals Corp.
  • Senior Management
  • James M Rae, CEO
    C. B Ackman, Pres.
    Michael A Adams, PhD, VP, Research
    James D Banting, PhD, VP, Bus. Dev.
    Jeremy P Heaton, MD, VP, Clinical Affairs
    Bruce Ackman, Pres.
  • Contact Info
  • Cellegy Canada Inc.
    Phone: (613) 545-9461
    116 Barrie St. Biosciences Complex
    Ste. 1606
    Kingston, K7L 3N6
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register